Authors
Loading...
Preclinical study reveals that METTL3 inhibits human stem cell cardiac differentiation via PRC2 and SMARCA2, indicating that targeted METTL3 degradation could enhance regenerative cell therapies.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: